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Abstract The melphalan-prednisone regimen has been con-
sidered as standard therapy for patients with multiple
myeloma (MM) for many years. Recently, high-dose
chemotherapy with stem-cell support has extended pro-
gression-free survival and increased overall survival, and it
is now considered conventional therapy in younger
patients. However, most patients relapse and the salvage
treatment is not very effective. New active drugs, including
immunomodulatory agents, thalidomide (Thal) and
lenalidomide, and the proteasome inhibitor bortezomib,
have shown promising anti-myeloma activity. These novel
treatments are aimed at overcoming resistance of tumour
cells to conventional chemotherapy, acting both directly on
myeloma cells and indirectly by blocking the interactions
of myeloma cells with their local microenvironment and
suppressing growth and survival signals induced by
autocrine and paracrine loops in the bone marrow. Thal has
been widely studied, mostly in combination regimens in
patients with relapsed MM and, more recently, in front-line
therapy, showing efficacy in terms of response rate and
event-free survival. Bortezomib has been found to possess
remarkable activity, especially in combination with other
chemotherapeutic agents, in relapsed/refractory and newly
diagnosed MM, as well as in patients presenting adverse
prognostic factors. Lenalidomide, in combination with dex-
amethasone, is showing high overall response rates in
relapsed and refractory MM and promising results also in
first-line therapy. In this paper, the results of the most sig-
nificant trials with Thal, bortezomib and lenalidomide are
reported. Several ongoing clinical studies will hopefully
allow the identification of the most active combinations
capable of improving survival in patients with MM.
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Introduction
Multiple myeloma (MM) is an aggressive and incurable
haematological neoplasia, characterised by expansion of
malignant plasma cells, which accounts for an estimated
14,000 new cases per year in the USA [1]. For many years,
the combination treatment with melphalan-prednisone
(MP) has been its conventional chemotherapy, resulting in
a median survival of about 3 years.
The frequency of remission, the disease-free survival
(DFS) and overall survival (OS) have been improved in
patients ≤65 years with the use of first-line high-dose
chemotherapy, followed by autologous stem-cell trans-
plantation (ASCT) [2, 3]. Indeed, two large randomised
trials have compared this procedure with standard
chemotherapy and the overall 5-year survival improved
from 12% to 52% in one trial (P=0.03), while the median
survival increased from 42 to 54 months in the second trial
(P=0.04) [4, 5]. Even so, most patients relapse and further
therapies are largely ineffective.
In the past 10 years, new advances have been gained
into the understanding of the biologic and molecular
mechanisms of MM pathogenesis. Several studies have
indeed shown a critical role of the bone marrow microen-
vironment in the development of this tumour. The interac-
tions of MM cells with stromal cells and extracellular
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Fax: +39-080-5478820matrix trigger paracrine and autocrine loops of many
cytokines involved in MM progression and activate intra-
cellular signal pathways that promote bone destruction as
well as survival, proliferation, drug resistance and genom-
ic instability of myeloma cells [6–9].
The identification of these mechanisms has led to the
development of novel therapeutic options to target specific
pathways involved in the pathogenesis of disease in order to
disrupt functional interactions between MM cells with bone
marrow microenvironment and to block autocrine self-sup-
porting circuits. These agents include the immunomodulato-
ry drug thalidomide (Thal), the proteasome inhibitor borte-
zomib, and the Thal derivative lenalidomide. Clinical studies
have shown encouraging results first in patients with
relapsed/refractory MM, then in newly diagnosed patients.
These drugs, alone and in combination, are now all approved
treatment options for symptomatic MM.
Thalidomide
Mechanism of action
Thal was introduced in the treatment of advanced MM in the
late 1990s, because of its antiangiogenic properties. These
were first described by D’Amato et al. [10], who showed that
Thal and its metabolites inhibit basic fibroblast growth fac-
tor (bFGF)-induced angiogenesis in a rabbit cornea microp-
ocket assay. The antiangiogenic activity of Thal metabolites
was further confirmed by other Authors [11–13]. More
recently, a significant decrease in bone marrow microvessel
density was demonstrated in patients who responded to Thal
[14] without reduction in the plasma level of angiogenic
cytokines [15], thus suggesting that different mechanism(s)
are involved in the antitumour effect of the drug.
Subsequently, these mechanisms have been progres-
sively disclosed. Thal has been shown to: (a) induce in
vitro growth arrest during the G1 phase and apoptosis by
either triggering activation of caspase-8 and/or increasing
the MM cell sensitivity to Fas-induced apoptosis [16, 17];
(b) block the increased secretion of tumour necrosis factor
alpha (TNF-α) by either enhancing TNF-α mRNA degra-
dation or neutralising α1-acid glycoprotein, a stimulator of
TNF-α secretion [18–20]; (c) modulate myeloma/stromal
cell interaction by either decreasing the expression of
adhesion molecules (ICAM-1,VCAM-1, E-selectin and L-
selectin) or inhibiting the paracrine loops of cytokine
secretion (particularly vascular endothelial growth factor
(VEGF) and interleukin (IL)-6) [21, 22]; (d) enhance host
immune response against MM, by the ability to increase
anti-CD3+ T-cell-induced proliferation and cytokine
secretion [IL-2 and interferon (IFN)-γ] in normal donors
[23] and/or by increasing in vivo CD56+ NK cell prolifer-
ation [24]; and (e) interfere with intracellular growth sig-
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nalling by down-regulating the constitutive activity of
nuclear factor kappa B (NFkB) (i.e., through the block of
insulin-like growth factor-1) [25, 26] as well as the expres-
sion of cellular inhibitor of apoptosis protein-2 (cIAP-2)
and FLICE inhibitory protein (FLIP), two well known
inhibitors of apoptosis [17] (Fig. 1).
The role of TNF-α is crucial, as indicated by
Thompson et al. [27] and Neben et al [28]. The former
investigators showed a poorer progression-free survival
(PFS) of Thal-treated MM patients if their pretreatment
serum TNF-α levels were elevated, while the second group
demonstrated a correlation between TNF-α gene polymor-
phism and response to Thal.
Clinical studies
Relapsed/refractory myeloma
The efficacy of Thal as a single agent or in combination in
the treatment of relapsed/refractory MM is described in
Table 1 [29–36]. Singhal et al. were the first to demonstrate
that Thal is effective in MM treatment [29]. In this phase II
study and its update on 169 patients (most of whom had
failed high-dose therapy) [30], a 30% partial response (PR)
and a 14% near complete response (nCR) were observed. A
2-year follow-up showed 20% and 48% event-free survival
(EFS) and OS rates respectively. Cytogenetic abnormalities
were associated with a poor prognosis.
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Fig. 1 Schematic representation of the effects of Thal and lenalido-
mide on myeloma cells, tumor microenvironment, and host immu-
nity. VCAM-1= vascular cell adhesion molecule 1; ICAM-1= inter-
cellular adhesion molecule 1; TNF-α= tumor necrosis factor alpha;
NFkB= nuclear factor kappa B; bFGF= basic fibroblast growth
factor; VEGF= vascular endothelial growth factor; IGF= insulin
growth factor; IL-6= interleukin 6; TGF-β= transforming growth
factor beta; IL-2= interleukin 2; IFNγ= interferon gamma
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THALIDOMIDE / LENALIDOMIDEMany other studies have demonstrated the efficacy of
Thal as a single agent in advanced MM with response rates
ranging from 25% to 64% [37–39].
Thal-Dexamethasone (Dex)
Preclinical studies have suggested synergistic activity of
Thal-Dex and clinical results have confirmed major efficacy
of this combination as compared with Thal alone [40, 41].
Dimopoulos et al. treated 44 patients with Thal (schedule is
shown in Table 1) [33]. Twenty-four patients (55%) achieved
a PR with a median time to response of 1.3 months. The
median time to progression for responding patients was 10
months and the median survival for all patients was 12.6
months. Similar encouraging results have also been reported
in another phase II study (Table 1) [32]. After 3 months of
treatment, 41% of patients reported objective response rates
(18% complete response (CR) and nCR). After a median fol-
low-up of 8 months, median PFS was 12 months.
Thal-Dex-pegylated liposomal doxorubicin (Doxil) or
Thal-Dex-cyclophosphamide (Cy)
The addition of Doxil to Thal-Dex increased the rate of
objective responses up to over 70% [42]. In a recent
prospective multicentre phase II study, 50 patients
received Thal-Dex and Doxil (40 mg/m2) (Table 1). The
overall response (OR) rate was 92%, with 26% CR, 6%
nCR and 44% PR [36]. The median PFS, EFS and OS were
22 months, 17 months and not reached, respectively.
A regimen that included cyclophosphamide (Cy) with
Thal-Dex showed objective responses in 79% of the 52
patients (17% of them reaching a CR) [35]. This combination
can induce a stable plateau phase and prolong stable disease.
Newly diagnosed MM
The efficacy of Thal as salvage treatment has led to the use
of this agent in newly diagnosed MM patients and to its
proposal as front-line therapy in preparation for subse-
quent ASCT [43, 44].
For many years, vincristine, doxorubicin and Dex
(VAD) has been used as standard pretransplantation induc-
tion therapy [45]. However, VAD has some disadvantages,
including the risk of catheter-related infection with related
thrombosis and toxicity (particularly, cardiac and neuro-
pathic), which limit the subsequent use of Thal or borte-
zomib in advanced phases of the disease. In a comparative
case-control study of 200 patients, the superiority of Thal-
Dex over VAD was reported with a significantly higher
response rate (76% vs. 52%; P<0.001) [46] (Table 2)
[46–52]. In each of the 2 treatment groups, 91% of patients
proceeded to peripheral blood stem-cell mobilisation.
Recently, in a phase 3 randomised study, Thal-Dex
combination therapy has been compared to Dex alone in
207 patients eligible for ASCT [48]. The OR was signif-
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Table 1 Response and survival of refractory/relapsed myeloma patients following thalidomide-based therapy
Patients Schedule Response  (%) Survival  Reference
(no.) (%/evaluation year)
Drugs Dose Time PR CR+nCR OR EFS OS
84 Thal 200–800 mg/day Continuous – – 32 22±5/1 58±5/1 [29]
169 Thal 200–800 mg/day Continuous 30 14 44 20±6/2 48±6/2 [30]
83 Thal 400 mg/day Continuous 35 13 48 78/1a 87/1a [31]
77 Thal 100 mg/day Continuous 23 18 41 1b – [32]
Dex 40 mg/day Days 1–4/month
44 Thal 200–400 mg/day Continuous 55 – 55 – 1.05c [33]
Dex 20 mg/m2 Days 1–4, 9–12, 17–20,
then 1–4
71 Thal 200–800 mg/day Continuous 55 2 57 57/2b 66/2 [34]
Cy 50 mg/day Continuous
Dex 40 mg/day Days 1–4 every 3 weeks
52 Thal 100–300 mg/day Continuous 62 17 79 34/2 73/2 [35]
Cy 300 mg/m2 1 every week
Dex 40 mg/day Days 1–4 every 4 weeks
50 Thal 100 mg/day Continuous 44 32 92 61/1 79/1 [36]
Doxil 40 mg/m2 Days 1
Dex 40 mg/day Days 1–4, 9–12
aPatients with favourable prognostic markers; bprogression-free survival (PFS); cmedian OS in years
PR, partial response; CR, complete response; nCR, near complete response; OR, overall response; EFS, event-free survival; OS, overall
survival ; Thal, thalidomide; Dex, dexamethasone; Doxil, pegylated liposomal doxorubicin; Cy, cyclophosphamideicantly higher with Thal-Dex than Dex alone (63% vs.
41% respectively, P=0.0017), with CR in 4% of patients.
Disease progression was noted in 2% of patients with
Thal-Dex and 5% of patients with Dex alone. Stem-cell
harvest was successful in 90% of patients in each arm.
However, combination therapy was associated with more
severe nonhaematologic toxicity ≥ grade 3 (67% vs. 43%).
Thromboembolic events, especially deep venous thrombo-
sis (DVT), occurred more frequently in the Thal-Dex arm
(17% vs. 3%, P<0.001). The evaluation of OS was not an
endpoint in this study, because the trial was intended to
assess the efficacy of pretransplantation induction therapy.
The capacity to further prolong survival and to improve
the outcome of patients with MM has been evaluated in a ran-
domised phase III study. Patients (668) were enrolled to
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receive two cycles of high-dose melphalan supported by
ASCT either with Thal (400 mg daily during induction
chemotherapy, 100 mg daily between transplantations, 200
mg daily with consolidation therapy, 100 mg daily during the
first year of maintenance therapy and 50 mg on alternate
days) or not [47]. After a median follow-up of 42 months, the
CR rate in the Thal group was 62% vs. 43% in the control
group (P<0.001), and the 5-year EFS was 56% vs. 44%
(P=0.01). Even so, the five-year OS did not statistically differ
between the two groups (65% in both groups, P=0.90) and
the median survival after relapse was lower in the Thal group
(1.1 years) than in the control group (2.7 years) (P<0.001).
The occurrence of adverse events (DVT and pulmonary
embolism) was higher in the Thal group (30% vs. 17% of
the control group). The addition of low-molecular-weight
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Table 2 Response and survival of newly diagnosed myeloma patients following Thal-based therapy in comparative trials
Patients Schedule Response  (%;  P) Survival Reference
(no.) (%; p/evaluation-year)
Drugs Dose Time PR CR+nCR OR EFS OS
200 Thal 100–200 mg/day Continuous 63 vs. 39; 13  vs. 13; 76  vs. 52; – – [46]
Dexa 40 mg Days 1–4, NAb NA <0.001
9–12, 17–20 
then 1–4
668 Thal 100–400  mg/day Continuous – 62  vs. 43; 62  vs. 43; 56  vs. 44; 65  vs. 65; [47]
high- <0.001 <0.001 =0.01/5 =0.09/5
dose
therapyc
207 Thal 200 mg/day Continuous – 4 63 vs. 41; – – [48]
Dexd 40 mg Days 1–4, =0.0017
9–12, 17–20
255 Thal 100 mg/day Continuous 60.4 vs. 45.2; 27.9  vs. 7.2; 76  vs. 47.6; 54  vs. 27; 80  vs. 64; [49]
Melphalan 4 mg/m2 Days 1–7 <0.0001 <0.0001 <0.0001 =0.0006/2 =0.19/3
Prednisone 40 mg/m2 Days 1–7
(MPT)e
50 Thal 300 mg/day Days 1–4, 62 10 72 – – [50]
17–20
Melphalan 8 mg/m2 Days 1–4
Dex 20 mg/m2 Days 1–4,
17–20
597 Thal 100 mg/day Continuous 30 vs. 37 vs.37; 67 vs. 57 vs. 55; 97 vs. 97 vs. 92; 52 vs. 37 vs. 36; 87 vs. 74 vs. 77;[51]
Pamidronatef 90 mg/m2 Day 1 every  =0.001 =0.001 =0.001 <0.009/3 <0.04/4
4 weeks
112 Thalg 200 mg/day Continuous – – – – 5.4 vs 3.8; [52]
=0.09h
avs. VAD; bNA, not applicable; cvs. no Thal; dvs. Dex; evs. MP; fvs. pamidronate vs. no maintenance; gmaintenance in post-transplantation;
hmedian OSheparin given prophylactically, starting after three years
from the beginning of the study, did not reduce the risk.
Moreover, the incidence of debilitating peripheral neuropa-
thy (>grade 2) was more frequent in the Thal group than in
the control group (27% vs. 17%, P<0.001). These results
indicate that: (a) Thal failed to improve OS; (b) it was asso-
ciated to severe toxic effects; and (c) CR was not necessar-
ily correlated to a longer survival. When the relapsed
patients received salvage therapies, the response rate was
higher and the survival longer in the patients who did not
receive Thal, suggesting that the drug may also induce
resistance to following treatments in relapsed patients.
However, some studies showed encouraging results
with the use of Thal as maintenance therapy following
high-dose chemotherapy/ASCT [53, 54]. In a randomised
phase III study, conducted by the InterGroupe Francophone
du Myélome, 597 patients were assigned to receive mainte-
nance therapy with Thal (100 mg daily) plus pamidronate
(PAM), maintenance with PAM alone or no maintenance
[51]. A CR or very good partial response (VGPR) was
achieved by 67% of patients in the group receiving Thal-
PAM, 57% in the group of PAM alone and 55% in the
group with no maintenance. Thal-PAM increased 3-year
EFS compared to the other two groups (52% vs. 37% and
36%, respectively; P<0.009) as well as the probability of 4-
year OS (87% vs. 74% and 77%; P<0.04).
In a recent retrospective study on 112 patients under-
going ASCT, it has been demonstrated that patients receiv-
ing Thal-based maintenance treatment had a higher medi-
an survival (65.5 months) as compared with patients (44.5
months) who did not receive Thal (P=0.09) [52]. Based on
these results, the post-transplant use of low-dose (50–100
mg) Thal as maintenance treatment appears to be promis-
ing, because of the lower incidence of adverse events
(thromboembolic risk and peripheral neuropathy) and of
developing drug resistance.
MP and Thal (MPT)
In patients over 60, who are not eligible for bone-marrow
transplantation, the results of a phase III randomised trial
conducted by Palumbo et al. showed that the addition of
Thal to MP in elderly patients is more active than standard
MP [49]. One hundred and twenty-nine out of 255 enrolled
patients received Thal (100 mg daily until progression or
relapse) and oral MP for six 4-week cycles. These patients
had higher response rates and longer EFS than patients
treated with MP alone. Combined CR and PR rates were
76% for MPT and 47.6% for MP alone, and the nCR or CR
rates were 27.9% and 7.2%, respectively. Two-year EFS
was 54% for MPT and 27% for MP (P=0.0006). Three-
year survival rates were 80% for MPT and 64% for MP
(P=0.19). The grade 3 or 4 adverse events of MPT com-
pared with those of MP were 48% vs. 25%. The addition
of enoxaparin prophylaxis reduced the rate of thromboem-
bolism from 20% to 3% (P=0.005).
Thus, therapy with Thal is effective, even if not cura-
tive, in the patients with symptomatic MM and can offer
the advantage of oral administration.
Bortezomib
Mechanism of action
Bortezomib is representative of a class of peptide boronate
proteasome inhibitors, which target the 26S proteasome, a
multicatalytic proteinase complex involved in intracellular
protein degradation [55].
A variety of proteins that regulate cell-cycle progres-
sion, signal transduction, gene expression, apoptosis,
immune response and angiogenesis are tagged for degra-
dation by polyubiquitin chains. The ubiquitin-tagged pro-
teins entering the proteasome are stripped of their ubiqui-
tin and cleaved. Bortezomib has high affinity, specificity
and selectivity for catalytic activity of the proteasome. It
ultimately inhibits the activation of the transcription factor
NF-kB by protecting its inhibitor (IkB) from degradation
by the proteasome complex (Fig. 2).
NF-kB is a transcription factor constitutively active in
MM and, when it is bound to its inhibitor IkB, it is retained
in the cytoplasm [8, 56, 57]. Degradation of IkB by pro-
teasome activates NF-kB, which moves to the nucleus and
up-regulates transcription of proteins that promote cell
survival and growth, reduce susceptibility to apoptosis,
influence the expression of adhesion molecules and induce
drug resistance in myeloma cells. Bortezomib can also
directly induce apoptosis of primary and drug-resistant
myeloma cell lines by interfering with the caspase-depen-
dent pathway, by down-regulating IL-6 and up-regulating
p53 and the cell-cycle inhibitor p27 [58, 59].
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Fig. 2 Mechanism of action of bortezomib. P, phosphorylated pro-
tein; IkB, nuclear factor kB inhibitory proteinFurthermore, bortezomib acts in the bone marrow
microenvironment by inhibiting the binding of MM cells
to bone marrow stromal cells, bone marrow-triggered
angiogenesis and/or cytokine (particularly IL-6) transcrip-
tion/secretion involved in the growth, survival and migra-
tion of myeloma cells and in the bone marrow angiogene-
sis [58, 60].
The results of recent studies suggest that bortezomib
inhibits osteoclastic bone resorption and increases
osteoblastic function [61–64], thus counteracting the lytic
processes triggered by myeloma cells.
Clinical studies
Relapsed/refractory myeloma
Bortezomib has been approved for the treatment of
relapsed/refractory MM in the USA and Europe on the
basis of results of two phase 2 clinical trials, namely
SUMMIT and CREST, and of the multicentre randomised
phase 3 APEX study [65–67]. This trial, conducted on
669 patients who relapsed after the first-, second- or
third-line therapies, compared bortezomib with standard
high-dose Dex and demonstrated a higher efficacy of
bortezomib than Dex in terms of response rate, time to
progression (primary endpoint) and OS. The results of
these trials are summarised in Table 3 [65–69]. An APEX
subgroup analysis demonstrated the efficacy of borte-
zomib also in elderly high-risk patients (β2-microglobu-
lin level >2.5 mg/l, >65 years of age, refractory to previ-
ous therapy and >1 previous line of therapy).
Furthermore, bortezomib was more effective in patients
who received the drug as second- than as third- and
fourth-line treatment (45% vs. 26% P=0.004). At 8.3-
months median follow-up, the median duration of
response was significantly longer in first relapsed
patients treated with bortezomib than in those with Dex
(8.1 vs. 6.2 months, respectively).
More recently, an updated analysis of the APEX trial
confirmed significant benefits of bortezomib after a longer
follow-up (median 22 months) as far as time to progression
and duration of response were concerned. The OR (CR and
PR) improved from 38% to 43% and the CR and nCR rate
increased to 16% [70]. In this trial, the most prominent
bortezomib-dependent adverse events were grade 3–4 (8%
of patients) and grade 1–2 (28% of patients) peripheral
neuropathy. Gastrointestinal disorders were: grade 1–2
diarrhoea (50%), vomiting (35%), nausea (57%), constipa-
tion (42%) and grade 1–2 fatigue (37% of patients). Herpes
zoster infection was common during the treatment (13% vs.
5% of patients of the Dex group; P<0.001). Grade 3–4
thrombocytopenia was also more frequent (30% vs. 6% of
Dex group), but reversible in a short time.
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Bortezomib-Dex
Of the 256 patients enrolled in the SUMMIT (n=202) and
CREST (n=54) studies, 106 patients (41%) who had a sub-
optimal response, in addition to bortezomib, received Dex
at the third or fourth cycle (20 mg on the day of and the
day after each dose of bortezomib) [71]. Thirteen (18%)
patients from SUMMIT and 9 (33%) from CREST had
improved responses to the combined treatment, including
the 8 patients (6 out of 13 and 2 out of 9 from SUMMIT
and CREST study respectively) who had been refractory to
previous Dex regimen alone. Nevertheless, the median
time to progression in this subset of patients was shorter
than in the whole population of patients both in SUMMIT
and CREST studies (5.3 vs. 6.9 months and 6.8 vs. 10.6
months, respectively).
Bortezomib-melphalan
To improve survival of patients with relapsed or refractory
MM and overcome chemotherapy resistance, additional
combinations have been considered.
In a phase I/II trial on 35 patients, which included the
association of bortezomib plus low doses of oral melpha-
lan, CR and PR were achieved in 47% of them (6% of CR
and 9% of nCR) [68]. Median PFS was 8 months (Table 3).
The addition of Dex to this combined therapy improved
response rates up to 80% [72].
Bortezomib-Cy and bortezomib-Doxil
The combination bortezomib, Dex and Cy was shown to be
significantly more effective than bortezomib alone or
bortezomib and Dex (OR rates were 64% vs. 30% and 47%
in 42 evaluable patients) [73].
In a phase 1 study on 22 evaluable patients, the associ-
ation of bortezomib and Doxil demonstrated significant
antitumour activity in advanced MM, with an OR rate of
73%, including 36% of CR or nCR [74]. An additional fol-
low-up on all patients revealed a median time to progres-
sion of 9.3 months, and a median OS of 38.3 months [75].
These findings have suggested the possibility that this
combination treatment may be very effective in
relapsed/refractory MM. Actually, a multicentre ran-
domised phase 3 study on 646 patients comparing the
combination of Doxil and bortezomib vs. bortezomib
alone has confirmed these encouraging results [76].
Bortezomib-MP-Thal (VMPT)
Among the bortezomib-based combinations, the addition of
immunomodulatory drugs is also being investigated. In a
recent multicentre phase I/II study, Palumbo et al. evaluated
the efficacy and tolerability of VMPT on 30 patients to iden-
tify the most appropriate and effective dose of bortezomib in
the MPT regimen [69] (Table 3). The maximum tolerated
dose of bortezomib was 1.3 mg/m2. Sixty-seven percent of
patients achieved a PR and 43% of these had a VGPR. A CR
was observed in the subset of patients who received this reg-
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rimen as second-line treatment (36%). The 1-year PFS and 1-
year OS were 61% and 84%, respectively.
Other bortezomib-based combination regimens
Many other combination regimens including Thal and
lenalidomide have been considered, such as bortezomib-
Doxil-Thal or bortezomib-Thal-Dex or bortezomib–
lenalidomide [77–79]. Most phase I or II studies reported
response rates of about 60%, with improvement of median
PFS and OS compared to standard regimens of chemothera-
py. These results are promising and raise the suggestion that
bortezomib, in association with either conventional or novel
active agents, may offer a valid treatment option in relapsed
and refractory patients presenting adverse prognostic factors
such as increased β2-microglobulin, cytogenetic abnormali-
ties (chromosome 13 deletion) and/or renal failure.
Newly diagnosed MM
Bortezomib is currently being evaluated as a first-line
treatment in previously untreated patients either ineligible
or candidates for ASCT in ongoing clinical trials. In the
front-line setting, bortezomib was studied as a single agent
in a multicentre phase 2 study in 63 patients (46 of them
evaluable for response) with a median age of 60 years [80].
Eleven, 20 and 28% of patients obtained a complete, par-
tial and minimal response respectively, giving an OR rate
of 59%. The most common adverse events were peripher-
al neuropathy (55% treatment-related) of mild to moderate
severity, and fatigue, rash, nausea, constipation and infec-
tion by Varicella zoster virus.
Bortezomib-MP
Mateos et al. performed a phase 1–2 study involving 60
untreated patients aged ≥65 (median age 74 years) with the
aim of determining efficacy and safety of bortezomib plus
standard MP [81]. The administration schedule and
90
response rates are indicated in Table 4 [81, 82]. Responses
were not conditioned by cytogenetic abnormalities, such
as retinoblastoma gene deletion, IgH translocations and
t(11; 14), t(4; 14), t(14; 16). Principal adverse effects
≥grade 3 were haematologic (thrombocytopenia 46% and
neutropenia 39%), gastrointestinal (23%), peripheral neu-
ropathy (15%) and infections (14%). The results seem to
be superior to those of historical data with MP, suggesting
this combination as a valid option to standard MP in elder-
ly patients who are not eligible to transplantation.
Presently, an international phase 3 randomised trial
(VISTA) comparing VMP with standard MP is ongoing to
determine if this combined therapy could be a standard of
care in replacing MP.
Bortezomib and ASCT
The rationale behind the use of bortezomib as part of
induction therapy stems from the observation that the drug
does not have meaningful toxic effects on haematopoietic
stem cells and that a successful mobilisation and quality of
the haematopoietic graft could be obtained following its
administration. Indeed, the combination of bortezomib-
Dex has been shown to be a very effective induction ther-
apy. In a phase II trial, when dexamethasone was added to
bortezomib in 36 of 48 patients who had achieved less than
a PR after 2 cycles of treatment with bortezomib as
monotherapy or less than a CR after 4 cycles, the response
to bortezomib improved in 64% of patients [83]. At the
end of treatment, the OR rate was 88% (CR and nCR 25%
and minimal response 8%). After a median follow-up of 24
months, the median time to alternative therapy for patients
not undergoing high-dose therapy was 22 months and 1-
year survival rate was 80%. Post-transplantation 1-year
survival rate was 90%. A very similar rate of CR (21%)
was obtained in another multicentre open-label phase II
trial with 52 patients, when Dex was administered from
the beginning of the study (schedule is shown in Table 4)
[82]. The stem cell collection was successful in most
patients (88%) and the toxicity was manageable.
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Table 4 Response and survival of newly diagnosed myeloma patients following bortezomib-based therapy
Patients Schedule Response  (%) Survival  Reference
(no.) (%/evaluation months)
Drugs Dose Time Cycles  PR CR+nCR OR EFS OS
(days) (no.)
60 Bortezomib 1.3 mg/m2 1,4,8,11,22, 4 46 43 89 83/16 90/16 [81]
25,29,32
1,8,15,22 5
Melphalan 9 mg/m2 1–4 9
Prednisone 60 mg/m2 1–4 9
52 Bortezomib 1.3 mg/m2 1,4,8,11 4 45 21 66 – – [82]
Dex 40 mg 1–4, 9–12 2
then 1–4 2Although it has not been shown that achieving a better
response is associated with overall improved survival after
transplantation, these results provide the rationale for the
ongoing phase III randomised trial planning to enrol 480
patients to compare bortezomib plus Dex regimen with stan-
dard induction treatment VAD [84]. The results from the inter-
im analysis, presented at the American Society of Hematology
meeting in 2006, are promising (response rate of bortezomib-
Dex vs. VAD: 20% vs. 10%), though not conclusive.
Bortezomib-doxorubicin-Dex (PAD)
In an initial trial, the PAD regimen induced overall CR
rates after 4 cycles of therapy of 29% and CR and VGPR
rates of 62% [85]. More recently, this combination has been
studied to determine if it can improve the quality of
response in patients who obtained a plateau PR after induc-
tion therapy [86]. The association is able to break this
plateau and to induce further cytoreduction, also achieving
a cytogenetic CR in 3/8 patients with chromosome 13 dele-
tion. The efficacy of doxorubicin in a steroid-free regimen
is being evaluated by Orlowski et al. in 63 patients who are
candidates for ASCT [87]. Preliminary response data avail-
able for 57 patients and presented at the American Society
of Hematology meeting in 2006 showed 16% CR or nCR
and 58% PR. Among 29 patients who completed the thera-
peutic programme, the CR and nCR were 28%, with an OR
rate of 79%. Furthermore, this therapeutic regimen allowed
an adequate collection of stem cells and was well tolerated.
Additional trials including bortezomib alone or in com-
bination are ongoing to evaluate its efficacy as front-line
therapy and the results seem promising, but many more
studies are required to provide clinical guidance, to define
how to use this agent and, finally, to establish if initial effi-
cacy can be translated into a real prolonged survival.
Lenalidomide
Mechanism of action
Lenalidomide is a Thal derivative, which has been devel-
oped to overcome the toxic nonhaematologic profile of
Thal, including its teratogenicity. It differs from Thal for
an amino group and is a more powerful inhibitor of TNF-
α activity. Similarly to Thal, lenalidomide is an anti-angio-
genic agent, inhibits the adhesion of myeloma cells to
bone marrow stromal cells, reduces the secretion of growth
and survival factors, induces direct apoptosis of myeloma
cells and promotes the cytotoxic activity of natural killer
and T-cells against human myeloma cells by stimulating
their proliferation and the secretion of IL-2 and IFN-γ [17,
88, 89] (Fig. 1). It also down-regulates the activity of
NFkB. These observations prompted the introduction of
lenalidomide for MM treatment.
Clinical studies
Relapsed/refractory MM
In phase I studies of patients with relapsed/refractory MM,
25 mg of lenalidomide daily was fixed as the maximum
tolerated dose [90]. The major dose-limiting toxic effect
was myelosuppression. Lenalidomide was evaluated in a
multicentre, open-label, randomised phase II trial of 70
patients by Richardson et al. [91]. The different schedules
of administration are shown in Table 5 [91–94]. Treatment
with lenalidomide alone resulted in OR, including CR and
PR or minor response, of 25%; median OS in the two
groups was similar (28 and 27 months, respectively), while
median PFS was higher in the first high-dose group (7.7
months vs. 3.9 months). Among 68 patients who received
Dex, response occurred in 29% of them. Myelosuppression
of grade 3 or 4 (thrombocytopenia and neutropenia)
occurred more frequently in patients who received 15 mg
twice daily (41% vs. 13%); peripheral neuropathy and
DVT were observed in 3% of the patients.
Two randomised phase 3 trials (MM-009 and MM-010)
have compared the combination lenalidomide plus high-
dose Dex vs. high-dose Dex alone, achieving similar
response rates in patients treated with the combination [95,
96]. In both studies, the group receiving lenalidomide and
Dex therapy reported remarkably higher OR rates (CR and
PR) than the Dex group (MM-009 61% vs. 20.5%,
P<0.001; MM-010 59.1% vs. 24%, P<0.001, respectively),
time to progression was better for combination therapy
than for Dex alone (MM-009: 11.1 vs. 4.7 months,
P<0.001; MM-010: 11.3 vs. 4.7 months, P<0.001, respec-
tively) and the same applied for OS (MM-009 29.6 vs. 20.5
months, P<0.001). The most common adverse event was
myelosuppression with thrombocytopenia and neutropenia
of grade 3 or 4, but the risk of venous thromboembolism
was much higher when lenalidomide was associated to
Dex. Differently from Thal, the incidence of peripheral
neuropathy, sedation and constipation was very low.
Lenalidomide–Doxil and lenalidomide–Cy
Lenalidomide has also been studied in combination with
other chemotherapeutic agents. Recently, the efficacy and
safety of a regimen comprising Doxil was studied in a
phase I/II trial of 62 patients with a median age of 62 years
(Table 5) [92]. After a median follow-up of 7.5 months, the
OR rate was 75%, and the rate of CR and nCR was 29%,
with a maximum tolerated dose of lenalidomide of 10 mg.
The median PFS was 12 months.
Also, the addition of an alkylating agent such as Cy has
been demonstrated to increase the response rate. In a ret-
rospective analysis, 21 patients of median age 59 years,
pretreated with various lines of chemotherapy (comprising
Thal, high-dose melphalan, bortezomib and allogeneic
bone marrow transplantation) were included [93]. The
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dobserved OR rate was 65% (CR and PR), with a toxicity
profile especially characterised by neutropenia (38%) and
DVT (14%).
Newly diagnosed MM
Lenalidomide–Dex
A phase 2 study evaluated a lenalidomide–Dex regimen as
induction therapy in 34 patients of median age 64 years
[94]. The treatment schedule is shown in Table 5. An
objective response was obtained in 91% of patients, and
6% of them achieved a CR, 53% a PR and 32% a VGPR.
Forty-four percent of patients proceeded to ASCT with an
adequate collection of stem cells. In 47% of patients, non-
haematologic toxicity of grade 3 or 4 was observed,
including fatigue (15%), muscle weakness (6%), pneu-
monitis (6%), anxiety (6%) and rash (6%). The incidence
of thromboembolic events was very low (3%), probably
because all patients initiated aspirin prophylaxis from the
very beginning.
Lenalidomide–MP
In patients ineligible for transplantation, lenalidomide-MP
has been evaluated in 54 patients aged ≥65 years [97]. The
OR rate was up to 85% with 23.8% of CR. Toxicity mainly
included myelosuppression, with neutropenia and thrombo-
cytopenia of grade 3–4 (66% and 34%, respectively).
Thromboembolic events were observed in 3 patients, though
all patients received prophylaxis with aspirin.
These combination regimens are promising and may
represent a valid alternative to Thal-based treatment, main-
ly because there are fewer non-haematologic adverse
events observed with lenalidomide.
Adverse events
Thalidomide
Besides the advantages of oral treatment for Thal and
lenalidomide, generally these drugs are well tolerated and
show a predictable and manageable toxicity profile.
Nevertheless, several side effects are related to their
administration, though with different severity.
Most of the adverse events correlate with dose and
duration of treatment. With doses lower than 400 mg daily,
their severity is mild to moderate. In addition to known
teratogenicity, frequently observed adverse events are:
sedation, somnolence, constipation, nausea, fatigue, cuta-
neous rash, bradycardia, hypothyroidism and oedema. The
most serious complications are peripheral neuropathy and
venous thromboembolism [98–101]. The incidence of the
former is very high (up to 50%) and seems to be related to
long-term use (generally over 6 months) and to a pretreat-
ment neuropathy [102]. The most frequent neuropathy-
related symptoms were numbness, paraesthesia or burning
sensation with involvement of hands and feet. Its definite
correlation with daily/cumulative dose [103] or with dura-
tion of treatment [104] has been confirmed. Thus, before
receiving Thal, patients should undergo neurological eval-
uation to identify those at higher risk for peripheral neu-
ropathy. In the initial phases of neuropathy, drug with-
drawal can increase the probability of recovery.
The incidence of thromboembolic events, especially
DVT and less commonly pulmonary embolism, seems to
be higher in patients with either newly diagnosed MM
(30% vs. 17% of control group) [47] and/or in Thal-
steroids combination regimens (17% vs. 3% of control
group) [48, 105]. On the basis of this evidence, the Authors
recommend routine prophylaxis with low-molecular-
weight heparin or warfarin or, in the patients with high
bleeding risk, aspirin. However, the efficacy of low-mole-
cular-weight heparin is an open question, because some,
but not all, Authors reported a considerable reduction in
the risk of DVT. Nevertheless, the generally held opinion
is that prophylaxis is recommended.
Lenalidomide
Lenalidomide has a better safety profile than Thal and the
most common adverse event is myelosuppression, particu-
larly neutropenia and thrombocytopenia ≥3 grade. But
lenalidomide is also associated with a high risk of DVT
when it is used with other agents, especially high-dose
Dex [106]. Dimopoulos et al. and Weber et al. reported
high rates of thromboses (9% and 17.5% respectively) in
patients receiving this combination therapy and the rate
was higher among patients who received concomitant ery-
thropoietic growth factors [107]. However, administration
of aspirin or salicylates seems to reduce the risk of DVT
[94, 108]. Therefore, aspirin or other antithrombotic drugs
should regularly be used in patients receiving this combi-
nation therapy and the concomitant use of erythropoietic
agents should be considered with caution.
Bortezomib
The toxicity profile of bortezomib is mainly characterised
by peripheral neuropathy and thrombocytopenia. Clinical
manifestations include paraesthesias, numbness and pain
affecting especially the lower extremities. Overall, the
investigators reported that 37% of patients had developed
a dose-related peripheral neuropathy of any grade, and
F. Merchionne et al.: New therapies in multiple myeloma 9314% of grade ≥3 within the first five cycles of treatment
[109]. The baseline neuropathy and previous therapies
with other neurotoxic agents, Thal, vincristine or plat-
inum, did not appear to affect the incidence of peripheral
neuropathy. Complete resolution or improvement of neu-
ropathic symptoms was observed in 71% of patients dur-
ing treatment by reducing the dose without compromising
the efficacy of therapy or completion of treatment.
In the APEX study, bortezomib was associated with
thrombocytopenia of grade ≥3 in 30% of patients, but this
effect was transient and the platelet count returned to normal
values between cycles with short time of recovery and with-
out cumulative effect. The cause and kinetics of bortezomib-
induced thrombocytopenia were different from those seen
with standard cytotoxic agents, given that bortezomib does
not induce cytotoxic effects on marrow megakaryocytes
[110]. Generally, thrombocytopenia is characterised by a
mean reduction in platelet counts from a baseline of approx-
imately 60%. Therefore, the most important predictor of
severe thrombocytopenia is the initial platelet count. Grade 3
or 4 thrombocytopenia occurs in patients who have low
platelet counts at baseline. Approximately 15% of patients
treated with bortezomib in the APEX study required transfu-
sions of platelets and this requirement peaked during the first
2 cycles and decreased with increasing cycles of treatment.
Moreover, the incidence of serious bleeding episodes associ-
ated with grade 3 thrombocytopenia was very low.
Conclusions
The use of targeted therapies exhibiting efficacy in MM is
certainly opening a new scenario in this tumour and is show-
ing promise to improve the outcome of these patients, even
though many randomised phase 3 studies are still required.
Despite impressive advances, the most important challenge
remains a better understanding of the disease biology, and to
identify additional and more specific targets either within
molecular genetics, especially gene expression profile,
involved in myelomagenesis or within bidirectional interac-
tions between myeloma cells and their microenvironment,
which promote not only growth and survival of malignant
cells, but also bone resorption and drug resistance.
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